Insider Buying Signals Confidence in CNS Pharma’s Pipeline Amid FDA Push for CN‑202
Investor alert: CNS Pharmaceuticals sees insider buying amid a 65% YTD decline, while CN‑202 shows 68% ORR in Phase II and CN‑315 hits new MTD thresholds—watch the pipeline, regulatory moves and capital strategy for a potential rebound.
3 minutes to read